These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20518136)

  • 41. Comment on the American Association of Oral and Maxillofacial Surgeons statement on bisphosphonates.
    Zahrowski JJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1440-1. PubMed ID: 17577522
    [No Abstract]   [Full Text] [Related]  

  • 42. Intravenous bisphosphonate treatment and osteonecrosis of the jaw in patients with cancer: wide CIs, Yule-Simpson and King Kong effects, and no therapeutic outcomes.
    Abraham I
    J Clin Oncol; 2010 Mar; 28(9):e143-4; author reply e145-7. PubMed ID: 20159796
    [No Abstract]   [Full Text] [Related]  

  • 43. Guidelines for treating patients taking bisphosphonates prior to dental extractions.
    Rogers S; Rahman N; Ryan D; Flint S; Healy C; Stassen LF
    J Ir Dent Assoc; 2010; 56(1):40. PubMed ID: 20337145
    [No Abstract]   [Full Text] [Related]  

  • 44. [Bisphosphonate-associated osteonecrosis of the jaws 1].
    Allard RH; Lips P; Eekhoff EM; van Merkesteyn JP; van der Waal I
    Ned Tijdschr Tandheelkd; 2007 Oct; 114(10):423-7. PubMed ID: 17972610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
    ; Khosla S; Burr D; Cauley J; Dempster DW; Ebeling PR; Felsenberg D; Gagel RF; Gilsanz V; Guise T; Koka S; McCauley LK; McGowan J; McKee MD; Mohla S; Pendrys DG; Raisz LG; Ruggiero SL; Shafer DM; Shum L; Silverman SL; Van Poznak CH; Watts N; Woo SB; Shane E
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1320-1; author reply 1321-2. PubMed ID: 18486811
    [No Abstract]   [Full Text] [Related]  

  • 46. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.
    Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons
    J Oral Maxillofac Surg; 2007 Mar; 65(3):369-76. PubMed ID: 17307580
    [No Abstract]   [Full Text] [Related]  

  • 47. Specialists play down risk of jaw condition.
    Stassen LF
    J Ir Dent Assoc; 2008; 54(4):153. PubMed ID: 18780680
    [No Abstract]   [Full Text] [Related]  

  • 48. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
    Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
    J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
    [No Abstract]   [Full Text] [Related]  

  • 49. Oral bisphosphonates and dental implants.
    McLeod NM
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1355. PubMed ID: 19446233
    [No Abstract]   [Full Text] [Related]  

  • 50. [Management of complications of bisphosphonates in oncology patients: jaw osteonecrosis].
    Madrid C; Jaques B; Bouferrache K; Broome M
    Rev Med Suisse; 2007 May; 3(112):1322, 1324-6, 1329-31. PubMed ID: 17596069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osteonecrosis of the jaw.
    Sykes DL
    Dent Today; 2007 Feb; 26(2):16. PubMed ID: 17348272
    [No Abstract]   [Full Text] [Related]  

  • 52. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?
    Junquera L; Gallego L
    J Oral Maxillofac Surg; 2008 Jul; 66(7):1516-7. PubMed ID: 18571043
    [No Abstract]   [Full Text] [Related]  

  • 53. For the dental patient. Osteoporosis medications and oral health.
    American Dental Association Division of Science
    J Am Dent Assoc; 2009 Jun; 140(6):812. PubMed ID: 19491171
    [No Abstract]   [Full Text] [Related]  

  • 54. Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?
    Aragon-Ching JB; Dahut WL
    Oncologist; 2008 Dec; 13(12):1314; author reply 1315. PubMed ID: 19088325
    [No Abstract]   [Full Text] [Related]  

  • 55. Bisphosphonate-associated osteonecrosis: experiences in a private practice.
    Marder MZ; Marder RW
    Dent Today; 2008 Oct; 27(10):99-100, 102-3; quiz 103, 98. PubMed ID: 18935863
    [No Abstract]   [Full Text] [Related]  

  • 56. Atrial fibrillation following intravenous zolendronic acid for osteoporosis.
    Konsta M; Bournia VK; Dania V; Iliopoulos A
    J Clin Rheumatol; 2014 Jun; 20(4):239-40. PubMed ID: 24847757
    [No Abstract]   [Full Text] [Related]  

  • 57. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
    Olson KB; Hellie CM; Pienta KJ
    Urology; 2005 Sep; 66(3):658. PubMed ID: 16140106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treating osteoporosis: do bisphosphonates really increase the risk of osteonecrosis of the jaw?
    Thompson E; Sheehy C; Barry M; Carey J
    Ir Med J; 2008 Jun; 101(6):166-7. PubMed ID: 18700507
    [No Abstract]   [Full Text] [Related]  

  • 59. Bisphosphonate-associated osteonecrosis of the jaw.
    Basu N; Reid DM
    Menopause Int; 2007 Jun; 13(2):56-9. PubMed ID: 17540134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Jaw osteonecrosis related to bisphosphonates: a new concern for dentistry.
    Geist RY; Geist JR; Aksu M
    J Mich Dent Assoc; 2005 Nov; 87(11):40-2. PubMed ID: 16372547
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.